Diabetes Congress 2019 : Serum CA19-9 level associated with metabolic control in diabetic patients - Radia Boufermes badji Mokhtar University

Abstract

Patients with type 2 diabetes are known to show raised serum levels of starch antigen 19‐9 (CA 19‐9). The point of the current examination was to research the potential connections of CA 19‐9 with metabolic control, insulin obstruction (IR ), and pancreatic β‐cell work in patients with corpulence and type 2 diabetes who experienced Roux‐En‐Y gastric detour (RYGB ). verified that starch antigen 19‐9 (CA19‐9) is a tumor‐associated antigen. CA19‐9 was initially characterized by a monoclonal neutralizer created by a hybridoma arranged from murine spleen cells inoculated with a human colorectal malignancy cell line. In people, CA19‐9 is communicated by the exocrine pancreas in vivo , and is raised in the blood of numerous patients with pancreatic diseases, malignancies of the upper gastrointestinal tract, ovarian malignant growth, hepatocellular malignant growth and colorectal cancer2. Besides, this antigen has a high incentive during the determination of pancreatic malignancy, since it has an affectability of 70–90% and a particularity of 68–91%3.